BLASUBCUTANEOUSINJECTION, SOLUTION
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Otulfi (ustekinumab-aauz) by Fresenius Kabi is interleukin-12 antagonists [moa]. First approved in 2025.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Otulfi (ustekinumab-aauz) is a monoclonal antibody antagonist of interleukin-12, a key cytokine in immune-mediated inflammatory conditions. This is a biosimilar or follow-on biologic formulation of an established IL-12 inhibitor platform. The drug targets patient populations with IL-12-driven immune disorders requiring subcutaneous administration.
LAUNCH
Early-stage launch product from Fresenius Kabi with moderate competitive pressure (30), offering growth potential for commercial teams building market presence in an established therapeutic class.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Otulfi represents a launch-stage opportunity within Fresenius Kabi's oncology and immunology portfolio, offering roles in brand building, field sales, and market access execution. Career growth potential is moderate, tied to the product's ability to gain traction in a competitive IL-12 antagonist market.
Brand ManagerField Sales Representative
Worked on Otulfi at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.